BNKL
Bionik Laboratories Corp. [BNKL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BNKL Stock Summary
In the News
BNKL Financial details
Company Rating
Neutral
Market Cap
1.2M
Income
-2.52M
Revenue
1.08M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
06 Feb 2024
P/E
-0.19
Forward P/E
-
PEG
0.02
P/S
0.77
P/B
-0.43
P/C
-
P/FCF
-0.56
Quick Ratio
0.38
Current Ratio
1.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.36
EPS next Y
-
EPS next Q
-
EPS this Y
74983.15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
239.12%
Revenue last 5Y
-11.07%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-109%
ROE
672%
ROC
-3.28%
Gross Margin
53%
Oper. Margin
-221%
Profit Margin
-235%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.031-2.9
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
625
Volume
Perf Week
0%
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-1.319
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.1
Change
0%
BNKL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.37 | 0.48 | 0.23 | 0.22 | 0.26 | |
| Net income per share | -4.47 | -5.6 | -2.72 | -2.67 | -2K | |
| Operating cash flow per share | -3.91 | -2.03 | -0.9 | -0.71 | -0.49 | |
| Free cash flow per share | -3.95 | -2.07 | -0.9 | -0.71 | 7.27K | |
| Cash per share | 0.19 | 0.51 | 0.12 | 0.34 | 0.06 | |
| Book value per share | 11.6 | 2.99 | 0.64 | 0.5 | -0.24 | |
| Tangible book value per share | 0.28 | 0.18 | -0.39 | 0.5 | -0.26 | |
| Share holders equity per share | 11.6 | 2.99 | 0.64 | 0.5 | -0.24 | |
| Interest debt per share | 1.38 | 0.51 | 0.8 | 0.14 | 0.36 | |
| Market cap | 10.04M | 8.24M | 12.82M | 2.19M | 2.76M | |
| Enterprise value | 9.6M | 8.05M | 15.93M | 200.13K | 4.75M | |
| P/E ratio | -0.95 | -0.33 | -0.92 | -0.14 | 0 | |
| Price to sales ratio | 3.09 | 3.83 | 10.74 | 1.72 | 1.53 | |
| POCF ratio | -1.09 | -0.91 | -2.77 | -0.53 | -0.82 | |
| PFCF ratio | -1.08 | -0.89 | -2.77 | -0.53 | 0 | |
| P/B Ratio | 0.37 | 0.62 | 3.91 | 0.75 | -1.68 | |
| PTB ratio | 0.37 | 0.62 | 3.91 | 0.75 | -1.68 | |
| EV to sales | 2.96 | 3.74 | 13.35 | 0.16 | 2.63 | |
| Enterprise value over EBITDA | -1.38 | -0.74 | -2.64 | -0.05 | -0.99 | |
| EV to operating cash flow | -1.04 | -0.89 | -3.45 | -0.05 | -1.4 | |
| EV to free cash flow | -1.03 | -0.87 | -3.45 | -0.05 | 0 | |
| Earnings yield | -1.05 | -3.02 | -1.09 | -7.12 | -5.01K | |
| Free cash flow yield | -0.93 | -1.12 | -0.36 | -1.9 | 18.17K | |
| Debt to equity | 0 | 0.16 | 1.13 | 0 | -1.47 | |
| Debt to assets | 0 | 0.11 | 0.42 | 0 | 0.72 | |
| Net debt to EBITDA | 0.06 | 0.02 | -0.52 | 0.45 | -0.42 | |
| Current ratio | 1.15 | 1.12 | 0.84 | 3.07 | 1.2 | |
| Interest coverage | -2.23 | -61.82 | -15.19 | -5.78 | -45.03 | |
| Income quality | 0.87 | 0.36 | 0.34 | 0.4 | 0.68 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.61 | 2.78 | 3.83 | 2.2 | 1.62 | |
| Research and developement to revenue | 0.98 | 1.81 | 1.25 | 0.78 | 0.5 | |
| Intangibles to total assets | 0.87 | 0.68 | 0.6 | 0 | 0.04 | |
| Capex to operating cash flow | 0.01 | 0.02 | 0 | 0 | -14.82K | |
| Capex to revenue | -0.03 | -0.07 | 0 | -0.01 | 27.8K | |
| Capex to depreciation | -0.29 | -0.42 | 0 | -0.12 | 794.48K | |
| Stock based compensation to revenue | 0.42 | 0.83 | 0.69 | 0.3 | 0.21 | |
| Graham number | 34.14 | 19.4 | 6.26 | 5.49 | 103.53 | |
| ROIC | -0.27 | -0.73 | -0.9 | -2.45 | -13.13K | |
| Return on tangible assets | -2.68 | -4.17 | -3.96 | -3.34 | -4.29K | |
| Graham Net | -0.19 | -0.39 | -0.58 | 0.18 | -0.54 | |
| Working capital | 479.41K | 626.92K | -662.19K | 3.09M | 468.38K | |
| Tangible asset value | 671.94K | 781.07K | -1.98M | 2.93M | -1.77M | |
| Net current asset value | 479.41K | 626.92K | -2.07M | 2.84M | -2.23M | |
| Invested capital | 0 | 0.16 | 1.13 | 0 | -1.47 | |
| Average receivables | 1.57M | 1.9M | 1.52M | 1.2M | 363.96K | |
| Average payables | 936.76K | 1M | 655.95K | 379.95K | 431.35K | |
| Average inventory | 321.56K | 732.57K | 875.81K | 941.59K | 1.11M | |
| Days sales outstanding | 325.73 | 154.47 | 652.19 | 78.76 | 91.61 | |
| Days payables outstanding | 257.23 | 350.18 | 615.67 | 347.51 | 249.63 | |
| Days of inventory on hand | 90.83 | 432.86 | 936.98 | 1.36K | 463.11 | |
| Receivables turnover | 1.12 | 2.36 | 0.56 | 4.63 | 3.98 | |
| Payables turnover | 1.42 | 1.04 | 0.59 | 1.05 | 1.46 | |
| Inventory turnover | 4.02 | 0.84 | 0.39 | 0.27 | 0.79 | |
| ROE | -0.39 | -1.87 | -4.25 | -5.33 | 8.44K | |
| Capex per share | -0.04 | -0.04 | 0 | 0 | 7.27K |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.07 | 0.08 | 0.07 | 0 | 0 | |
| Net income per share | -0.17 | -0.16 | -0.2 | 0 | 0 | |
| Operating cash flow per share | -0.14 | -0.07 | -0.11 | 0 | 0 | |
| Free cash flow per share | -0.13 | -0.07 | -0.11 | 0 | 0 | |
| Cash per share | 0.06 | 0.1 | 0.06 | 0 | 0 | |
| Book value per share | 0.08 | -0.08 | -0.24 | 0 | 0 | |
| Tangible book value per share | 0.06 | -0.1 | -0.25 | 0 | 0 | |
| Share holders equity per share | 0.08 | -0.08 | -0.24 | 0 | 0 | |
| Interest debt per share | 0.15 | 0.28 | 0.35 | 0 | 0 | |
| Market cap | 2.08M | 4.29M | 2.79M | 0 | 0 | |
| Enterprise value | 2.72M | 5.46M | 4.77M | 0 | 0 | |
| P/E ratio | -0.45 | -0.97 | -0.49 | 0 | 0 | |
| Price to sales ratio | 4.27 | 7.45 | 5.56 | 0 | 0 | |
| POCF ratio | -2.17 | -8.36 | -3.68 | 0 | 0 | |
| PFCF ratio | -2.3 | -9.26 | -3.68 | 0 | 0 | |
| P/B Ratio | 3.97 | -8.21 | -1.7 | 0 | 0 | |
| PTB ratio | 3.97 | -8.21 | -1.7 | 0 | 0 | |
| EV to sales | 5.59 | 9.5 | 9.52 | 0 | 0 | |
| Enterprise value over EBITDA | -2.47 | -5.33 | -3.72 | 0 | 0 | |
| EV to operating cash flow | -2.84 | -10.65 | -6.3 | 0 | 0 | |
| EV to free cash flow | -3 | -11.81 | -6.3 | 0 | 0 | |
| Earnings yield | -0.55 | -0.26 | -0.51 | 0 | 0 | |
| Free cash flow yield | -0.44 | -0.11 | -0.27 | 0 | 0 | |
| Debt to equity | 1.98 | -3.57 | -1.47 | 0 | 0 | |
| Debt to assets | 0.27 | 0.51 | 0.72 | 0 | 0 | |
| Net debt to EBITDA | -0.58 | -1.15 | -1.55 | 0 | 0 | |
| Current ratio | 1.59 | 1.47 | 1.2 | 0 | 0 | |
| Interest coverage | -63.8 | -34.28 | -23.81 | 0 | 0 | |
| Income quality | 0.85 | 0.48 | 0.56 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.41 | 1.35 | 1.73 | 0 | 0 | |
| Research and developement to revenue | 0.46 | 0.16 | 0.41 | 0 | 0 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.04 | 0 | 0 | |
| Capex to operating cash flow | -0.05 | -0.1 | 0 | 0 | 0 | |
| Capex to revenue | 0.1 | 0.09 | 0 | 0 | 0 | |
| Capex to depreciation | 4.05 | 2.53 | -0.04 | 0 | 0 | |
| Stock based compensation to revenue | 0.11 | 0.05 | 0.47 | 0 | 0 | |
| Graham number | 0.53 | 0.52 | 1.04 | 0 | 0 | |
| ROIC | -0.62 | -0.67 | -1.32 | 0 | 0 | |
| Return on tangible assets | -0.31 | -0.31 | -0.44 | 0 | 0 | |
| Graham Net | -0.26 | -0.39 | -0.53 | 0 | 0 | |
| Working capital | 1.2M | 983.81K | 468.38K | 0 | 0 | |
| Tangible asset value | 387.47K | -656.46K | -1.77M | 0 | 0 | |
| Net current asset value | -74.3K | -1.13M | -2.23M | 0 | 0 | |
| Invested capital | 1.98 | -3.57 | -1.47 | 0 | 0 | |
| Average receivables | 350.21K | 459.41K | 395.23K | 226.54K | 0 | |
| Average payables | 389.2K | 366.22K | 469.11K | 278.81K | 0 | |
| Average inventory | 1.38M | 1.25M | 1.09M | 517.24K | 0 | |
| Days sales outstanding | 107.63 | 52.8 | 81.37 | 0 | 0 | |
| Days payables outstanding | 167.85 | 112.5 | 203.18 | 0 | 0 | |
| Days of inventory on hand | 644.33 | 338 | 376.95 | 0 | 0 | |
| Receivables turnover | 0.84 | 1.7 | 1.11 | 0 | 0 | |
| Payables turnover | 0.54 | 0.8 | 0.44 | 0 | 0 | |
| Inventory turnover | 0.14 | 0.27 | 0.24 | 0 | 0 | |
| ROE | -2.19 | 2.12 | 0.86 | 0 | 0 | |
| Capex per share | 0.01 | 0.01 | 0 | 0 | 0 |
BNKL Frequently Asked Questions
What is Bionik Laboratories Corp. stock symbol ?
Bionik Laboratories Corp. is a US stock , located in Watertown of Ma and trading under the symbol BNKL
What is Bionik Laboratories Corp. stock quote today ?
Bionik Laboratories Corp. stock price is $0.1 today.
Is Bionik Laboratories Corp. stock public?
Yes, Bionik Laboratories Corp. is a publicly traded company.
Company Profile
- Volume Average 625
- Market Capitalization 1.2M
- Employee 12
- CEO Mr. Richard Paul Russo Jr., CPA
- Headquarters Watertown,MA,US
- IPO Date 2015-03-05
-
Website
https://www.bioniklabs.com 
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.
